Short answer
Protagonist Therapeutics, Inc (PTGX) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). First-quarter 2026 financial results reported for period ended March 31, 2026.
Protagonist Therapeutics, Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- First-quarter 2026 financial results reported for period ended March 31, 2026
- Press release provides detailed results and corporate update, furnished with the 8-K filing
Item EX-99.1 · Exhibit EX-99.1
- ICOTYDE FDA approval generated $50.0M Q1 milestone, plus 6%-10% global sales royalties and up to $580M additional milestones
- Rusfertide Priority Review targets FDA action in August 2026, creating a near-term regulatory catalyst
- Takeda opt-out provides $200M upfront, potential $200M additional fee, $75M approval milestone, up to $775M sales milestones, and 14%-29% royalties
- Q1 revenue rose to $56.4M from $28.3M, producing $3.8M net income versus $11.7M loss
- Cash, equivalents and marketable securities totaled $620.3M, supporting operations through at least 2028 and advancing PN-881 and PN-477
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Protagonist Therapeutics, Inc 8-K filings
Get the next PTGX 8-K as it lands
Follow PTGX for push alerts, or ask the research agent what this filing means.